MA52232A - Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer - Google Patents
Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancerInfo
- Publication number
- MA52232A MA52232A MA052232A MA52232A MA52232A MA 52232 A MA52232 A MA 52232A MA 052232 A MA052232 A MA 052232A MA 52232 A MA52232 A MA 52232A MA 52232 A MA52232 A MA 52232A
- Authority
- MA
- Morocco
- Prior art keywords
- heterbicyclic
- mat2a
- inhibitors
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018081328 | 2018-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA52232A true MA52232A (fr) | 2021-02-17 |
Family
ID=67439309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052232A MA52232A (fr) | 2018-03-30 | 2019-03-28 | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer |
Country Status (18)
Country | Link |
---|---|
US (1) | US11524960B2 (fr) |
EP (1) | EP3774805B1 (fr) |
JP (2) | JP7350005B2 (fr) |
KR (1) | KR20200138769A (fr) |
CN (1) | CN111936499B (fr) |
AR (1) | AR115326A1 (fr) |
AU (1) | AU2019243289B2 (fr) |
BR (1) | BR112020020104A2 (fr) |
CA (1) | CA3094476A1 (fr) |
EA (1) | EA202092320A1 (fr) |
IL (1) | IL277665B2 (fr) |
MA (1) | MA52232A (fr) |
MX (1) | MX2020010005A (fr) |
PH (1) | PH12020551507A1 (fr) |
SG (1) | SG11202009195WA (fr) |
TW (1) | TWI719437B (fr) |
UA (1) | UA127059C2 (fr) |
WO (1) | WO2019191470A1 (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA54452A (fr) | 2018-12-10 | 2022-03-16 | Ideaya Biosciences Inc | Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a |
KR20220050832A (ko) * | 2018-12-27 | 2022-04-25 | 르 라보레또레 쎄르비에르 | Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법 |
US20220144820A1 (en) * | 2018-12-27 | 2022-05-12 | Les Laboratoires Servier Sas | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer |
PE20220387A1 (es) * | 2019-05-31 | 2022-03-18 | Servier Lab | Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer |
WO2021252680A1 (fr) * | 2020-06-10 | 2021-12-16 | Ideaya Biosciences, Inc. | Dérivés de 4-arylquinazoline en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a |
US20230257377A1 (en) * | 2020-06-10 | 2023-08-17 | Ideaya Biosciences, Inc. | 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors |
US20230227409A1 (en) * | 2020-06-10 | 2023-07-20 | Ideaya Biosciences, Inc. | Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors |
WO2021252678A1 (fr) * | 2020-06-10 | 2021-12-16 | Ideaya Biosciences, Inc. | Dérivés de 2-oxoquinazoline substitués par un alkylène hétéroaryle utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a |
CN115960098A (zh) * | 2020-09-11 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
TW202214630A (zh) * | 2020-09-12 | 2022-04-16 | 大陸商成都倍特藥業股份有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其製備方法及應用 |
WO2022063128A1 (fr) * | 2020-09-24 | 2022-03-31 | 上海凌达生物医药有限公司 | Composé de pyridone cyclique ou arylhétérocyclique aromatique, compositions pharmaceutiques et leur utilisation |
TW202227443A (zh) | 2020-12-31 | 2022-07-16 | 中國商江蘇先聲藥業有限公司 | 三環類化合物及用途 |
CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
CN115215862A (zh) * | 2021-04-19 | 2022-10-21 | 武汉人福创新药物研发中心有限公司 | 嘧啶酮化合物及其用途 |
CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
WO2023083210A1 (fr) * | 2021-11-09 | 2023-05-19 | 上海海雁医药科技有限公司 | Dérivé de naphtyridinone substitué, composition pharmaceutique de celui-ci et utilisation de celui-ci |
CN114028572B (zh) * | 2021-11-30 | 2022-11-25 | 清华大学 | Mat2a抑制剂用于治疗哮喘的新应用 |
WO2023116696A1 (fr) * | 2021-12-21 | 2023-06-29 | 南京正大天晴制药有限公司 | Inhibiteur hétérocyclique de la méthionine adénosyltransférase 2a |
WO2023125737A1 (fr) * | 2021-12-29 | 2023-07-06 | Silexon Ai Technology Co., Ltd. | Composés hétérocycliques et leur utilisation |
TW202333696A (zh) * | 2022-01-26 | 2023-09-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 用於治療mtap缺失型癌症的甲硫氨酸腺苷轉移酶2a抑制劑 |
WO2023169554A1 (fr) * | 2022-03-11 | 2023-09-14 | 赛诺哈勃药业(成都)有限公司 | Inhibiteur de méthionine adénosine transférase, son procédé de préparation et son utilisation |
CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999064400A1 (fr) | 1998-06-12 | 1999-12-16 | Vertex Pharmaceuticals Incorporated | INHIBITEURS DE p38 |
US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
AU2003250466A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors |
CA2779105C (fr) | 2009-10-29 | 2016-08-16 | Hong Woo Kim | Inhibiteurs de kinases |
US20160115164A1 (en) * | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
EP4047001A3 (fr) | 2016-07-05 | 2022-11-30 | The Broad Institute, Inc. | Inhibiteurs bicycliques d'urée kinase et leurs utilisations |
AU2017319500C1 (en) * | 2016-08-31 | 2022-10-20 | Les Laboratoires Servier | Inhibitors of cellular metabolic processes |
WO2018039972A1 (fr) * | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibiteurs de processus métaboliques cellulaires |
-
2019
- 2019-03-28 MA MA052232A patent/MA52232A/fr unknown
- 2019-03-28 SG SG11202009195WA patent/SG11202009195WA/en unknown
- 2019-03-28 US US17/040,614 patent/US11524960B2/en active Active
- 2019-03-28 EP EP19744896.2A patent/EP3774805B1/fr active Active
- 2019-03-28 WO PCT/US2019/024645 patent/WO2019191470A1/fr unknown
- 2019-03-28 BR BR112020020104-9A patent/BR112020020104A2/pt unknown
- 2019-03-28 EA EA202092320A patent/EA202092320A1/ru unknown
- 2019-03-28 AU AU2019243289A patent/AU2019243289B2/en active Active
- 2019-03-28 JP JP2020552849A patent/JP7350005B2/ja active Active
- 2019-03-28 UA UAA202006905A patent/UA127059C2/uk unknown
- 2019-03-28 KR KR1020207030741A patent/KR20200138769A/ko not_active Application Discontinuation
- 2019-03-28 MX MX2020010005A patent/MX2020010005A/es unknown
- 2019-03-28 CN CN201980023557.8A patent/CN111936499B/zh active Active
- 2019-03-28 CA CA3094476A patent/CA3094476A1/fr active Pending
- 2019-03-29 TW TW108111265A patent/TWI719437B/zh active
- 2019-03-29 AR ARP190100845A patent/AR115326A1/es unknown
-
2020
- 2020-09-18 PH PH12020551507A patent/PH12020551507A1/en unknown
- 2020-09-29 IL IL277665A patent/IL277665B2/en unknown
-
2023
- 2023-06-01 JP JP2023090963A patent/JP2023101762A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3774805B1 (fr) | 2024-01-10 |
MX2020010005A (es) | 2020-10-14 |
PH12020551507A1 (en) | 2021-09-13 |
KR20200138769A (ko) | 2020-12-10 |
CN111936499A (zh) | 2020-11-13 |
CA3094476A1 (fr) | 2019-10-03 |
US20210115045A1 (en) | 2021-04-22 |
EP3774805A1 (fr) | 2021-02-17 |
JP7350005B2 (ja) | 2023-09-25 |
WO2019191470A8 (fr) | 2019-12-12 |
AU2019243289B2 (en) | 2023-01-12 |
IL277665B2 (en) | 2023-06-01 |
WO2019191470A1 (fr) | 2019-10-03 |
SG11202009195WA (en) | 2020-10-29 |
UA127059C2 (uk) | 2023-03-29 |
AR115326A1 (es) | 2020-12-23 |
JP2023101762A (ja) | 2023-07-21 |
CN111936499B (zh) | 2023-09-19 |
IL277665A (en) | 2020-11-30 |
TWI719437B (zh) | 2021-02-21 |
TW201946629A (zh) | 2019-12-16 |
JP2021519783A (ja) | 2021-08-12 |
BR112020020104A2 (pt) | 2021-01-26 |
EA202092320A1 (ru) | 2021-03-09 |
AU2019243289A1 (en) | 2020-09-24 |
US11524960B2 (en) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
MA50082A (fr) | Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer | |
MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA52780A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
MA52564A (fr) | Inhibiteurs de kras g12c pour le traitement du cancer | |
MA54608A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA43811A (fr) | Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes | |
MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
MA52861A (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil | |
MA53873A (fr) | Compositions et procédés pour le traitement de la presbytie | |
MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques |